Dyno Therapeutics Emerges With Novartis, Sarepta Deals For Novel AAV Capsids
Dyno raised $9m in 2018 but came out of stealth mode with deals worth up to $2bn based on its platform using high throughput biology, AI and machine learning to engineer next-generation AAV capsids.
You may also be interested in...
Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.
Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.
BIO panel with Roche’s James Sabry, Spark’s Federico Mingozzi and Adaptive’s Harlan Robins imagines a world where cell and gene therapies are preferred over small molecules and antibodies.